Special Issue

Advances in Vaccine Development

Message from the Guest Editor

We are glad to announce the Special Issue entitled "Advances in Vaccine Development". We are soliciting reviews of manuscripts examining advances in gene delivery and expression, (nano)particles, proteins, and adjuvants creating the potential for new vaccine platforms. The review could cover strategic approaches for selecting vaccine antigens, formulations, or regimens, or review a field of vaccine research for specific diseases such as viruses. We would welcome a review or "perspective" discussing challenges ahead.

Guest Editor

Prof. Dr. Ralph A. Tripp Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Deadline for manuscript submissions

closed (30 April 2021)



an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 8.9 Indexed in PubMed



mdpi.com/si/58066

Vaccines MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 vaccines@mdpi.com

mdpi.com/journal/

vaccines





an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 8.9 Indexed in PubMed



vaccines



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).